Masakazu Nagahori

Masakazu Nagahori

Auto-generated profile, based on publicly available information

Masakazu Nagahori

Clinical Research Center, Tokyo Medical and Dental University Hospital, Tokyo, Japan

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 April 2020 in Digestive Diseases and Sciences
Verified
Journal Article
Closed access
PDF file
CWChikako Watanabe
Chikako Watanabe
MNMasakazu Nagahori
Masakazu Nagahori
TFToshimitsu Fujii
Toshimitsu Fujii
KYKaoru Yokoyama
Kaoru Yokoyama
NYNaoki Yoshimura
Naoki Yoshimura
RHRyota Hokari
Ryota Hokari

29 July 2021 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PDF file
KTKento Takenaka
Kento Takenaka
AKAmi Kawamoto
Ami Kawamoto
SHShuji Hibiya
Shuji Hibiya
KSKohei Suzuki
Kohei Suzuki
TFToshimitsu Fujii
Toshimitsu Fujii
KOKazuo Ohtsuka
Kazuo Ohtsuka

30 January 2021 in Intestinal Research
Verified
Journal Article
Open access
PDF file
HSHiromichi Shimizu
Hiromichi Shimizu
TFToshimitsu Fujii
Toshimitsu Fujii
SHShuji Hibiya
Shuji Hibiya
MMMaiko Motobayashi
Maiko Motobayashi
KSKohei Suzuki
Kohei Suzuki
MWMamoru Watanabe
Mamoru Watanabe

1 January 2014 in Digestion
Verified
Journal Article
Open access
PDF file
TFToshimitsu Fujii
Toshimitsu Fujii
MNMakoto Naganuma
Makoto Naganuma
YKYoshio Kitazume
Yoshio Kitazume
ESEiko Saito
Eiko Saito
MNMasakazu Nagahori
Masakazu Nagahori
MWMamoru Watanabe
Mamoru Watanabe
Crohn's disease (CD) is a lifelong chronic inflammatory bowel disease associated with diarrhea, abdominal pain, bloody stool and often perianal fistulae. Inflammation in CD involves the entire gastrointestinal tract, especially including the small and large bowels, causing irreversible bowel damage. Frequent imaging examinations are necessary to monitor disease activity and to evaluate response to therapeutic interventions, and, furthermore, to predict recurrence in order to provide appropriate treatment. The suitable imaging modality should be reproducible, well tolerated, safe and free of ionizing radiation. In recent years, imaging used in CD has dramatically changed. Cross-sectional imaging techniques such as computed tomography and magnetic resonance imaging (MRI) are used to investigate not only extraluminal abnormalities, but also intraluminal changes. Recently, new techniques such as MR enteroclysis, enterography, colonography and enterocolonography have been developed. These recent advances enable the use of MRI to assess bowel disorders with high sensitivity, specificity and accuracy. MRI can evaluate simultaneously the bowel surface, bowel wall, abdominal abscesses and perianal lesions, such as perianal fistulae and perianal abscesses, without the problem of overlapping bowel loops. Therefore, MRI has the potential for evaluation of the overall disease activity of CD without radiation exposure. We believe that MRI is a suitable first choice imaging modality in the assessment of CD.

1 March 2021 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Closed access
MKMiyuki Kaneshiro
Miyuki Kaneshiro
KTKento Takenaka
Kento Takenaka
KSKohei Suzuki
Kohei Suzuki
TFToshimitsu Fujii
Toshimitsu Fujii
SHShuji Hibiya
Shuji Hibiya
MWMamoru Watanabe
Mamoru Watanabe

4 April 2017 in BMC Gastroenterology
Verified
Journal Article
Open access
PDF file
OGOPTIMUM Study Group
OPTIMUM Study Group
MNMasakazu Nagahori
Masakazu Nagahori
SKShuji Kochi
Shuji Kochi
HHHiroyuki Hanai
Hiroyuki Hanai
TYTakayuki Yamamoto
Takayuki Yamamoto
THToshifumi Hibi
Toshifumi Hibi
Efficacy of maintenance therapy in ulcerative colitis (UC) in the remission stage has been reported to depend on release profile or dosing regimen of oral 5-aminosalicylic acid (5-ASA) products used. Aim of this study is to investigate real life results in using oral 5-ASA products for maintaining mild to moderate UC patients in Japan. Adult UC outpatients treated with oral 5-ASA products were enrolled from 379 sites in Japan between July 2012 and July 2013, and followed for 52 weeks. Remission maintenance rate was evaluated by products and dosages. Factors affecting recurrence were also examined. A total of 5695 UC patients were registered. Among the 4677 patients in whom remission maintenance was observed, remission maintenance rate at week 52 was 80.2%. As for disease duration and dosage, Pentasa® 4000 mg/day in 2 divided doses was administered to 480 (21.0%) patients in remission and 341 (46.6%) patients in active stage, and Asacol® 3600 mg/day in 3 divided doses was administered to 696 (46.4%) patients in remission and 473 (67.3%) patients in active stage. The remission maintenance rate at week 52 by dosage and frequency did not significantly differ between Pentasa® Tablets at 4000 mg/day in 2 divided doses (76.5%) and Asacol® Tablets at 3600 mg/day in 3 divided doses (76.1%, P = 0.7868). Factors affecting the risk of relapse in UC were identified. Significantly persistent remission maintenance was noted in patients in whom duration of remission maintenance until enrollment was 12 to <24 months or ≥24 months relative to the reference category of <3 months (12 to <24 months: HR 0.600 [0.486–0.740], p < 0.0001]; ≥24 months: HR 0.352 [0.289–0.431], p < 0.0001). Efficacy of real life results in using oral 5-ASA products for maintaining mild to moderate UC patients was favorable. Maintaining remission for 12 months or longer after induction therapy was shown to reduce recurrence risk thereafter. UMIN 000008563 (the date of registration: July 30, 2012), ClinicalTrials.gov NCT01654783 (the date of registration: July 30, 2012)